Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery

Woo Jin Shin, Baik Lin Seong

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: The emergence of the highly pathogenic avian influenza (HPAI) H5N1 virus and the recent global circulation of H1N1 swine-origin influenza virus in 2009 have highlighted the need for new anti-influenza therapies. This has been made all the more important with the emergence of antiviral-resistant strains. Recent progress in achieving three-dimensional (3D) crystal structures of influenza viral proteins and efficient tools available for pharmacophore-based virtual screening are aiding us in the discovery and design of new antiviral compounds. Areas covered: This review discusses pharmacophore modeling as a potential cost-effective and time-saving technology for new drug discovery as an alternative to high-throughput screening. Based on this technical platform, the authors discuss current progress and future prospects for developing novel influenza antivirals against pre-existing or emerging novel targets. Expert opinion: Although it might be at an infant stage of development, the availability of the 3D crystal structures of influenza viral proteins is expected to accelerate the application of structure-based drug design (SBDD) and pharmacophore modeling. Furthermore, the neuraminidase inhibitor, one of the most successful examples of a SBDD, still receives great attention because of its superb antiviral activities and the resistance of influenza strains to oseltamivir. However, despite much success, pharmacophore-based virtual screening exhibits limited predictive power in hit identification. Further improvements in pharmacophore detection algorithms, proper combinations of in silico methods as well as judicious choosing of compounds are expected to improve the hit rate. With the help of these technologies, the discovery of anti-influenza agents will be accelerated.

Original languageEnglish
Pages (from-to)411-426
Number of pages16
JournalExpert Opinion on Drug Discovery
Volume8
Issue number4
DOIs
Publication statusPublished - 2013 Apr 1

Fingerprint

Drug Discovery
Human Influenza
Antiviral Agents
Drug Design
Viral Proteins
Orthomyxoviridae
H5N1 Subtype Influenza A Virus
Technology
Oseltamivir
Influenza in Birds
Expert Testimony
Neuraminidase
Child Development
Computer Simulation
Swine
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Drug Discovery

Cite this

@article{c0fbd406ae204a4ea5b6d657add2167d,
title = "Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery",
abstract = "Introduction: The emergence of the highly pathogenic avian influenza (HPAI) H5N1 virus and the recent global circulation of H1N1 swine-origin influenza virus in 2009 have highlighted the need for new anti-influenza therapies. This has been made all the more important with the emergence of antiviral-resistant strains. Recent progress in achieving three-dimensional (3D) crystal structures of influenza viral proteins and efficient tools available for pharmacophore-based virtual screening are aiding us in the discovery and design of new antiviral compounds. Areas covered: This review discusses pharmacophore modeling as a potential cost-effective and time-saving technology for new drug discovery as an alternative to high-throughput screening. Based on this technical platform, the authors discuss current progress and future prospects for developing novel influenza antivirals against pre-existing or emerging novel targets. Expert opinion: Although it might be at an infant stage of development, the availability of the 3D crystal structures of influenza viral proteins is expected to accelerate the application of structure-based drug design (SBDD) and pharmacophore modeling. Furthermore, the neuraminidase inhibitor, one of the most successful examples of a SBDD, still receives great attention because of its superb antiviral activities and the resistance of influenza strains to oseltamivir. However, despite much success, pharmacophore-based virtual screening exhibits limited predictive power in hit identification. Further improvements in pharmacophore detection algorithms, proper combinations of in silico methods as well as judicious choosing of compounds are expected to improve the hit rate. With the help of these technologies, the discovery of anti-influenza agents will be accelerated.",
author = "Shin, {Woo Jin} and Seong, {Baik Lin}",
year = "2013",
month = "4",
day = "1",
doi = "10.1517/17460441.2013.767795",
language = "English",
volume = "8",
pages = "411--426",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "4",

}

Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. / Shin, Woo Jin; Seong, Baik Lin.

In: Expert Opinion on Drug Discovery, Vol. 8, No. 4, 01.04.2013, p. 411-426.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery

AU - Shin, Woo Jin

AU - Seong, Baik Lin

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Introduction: The emergence of the highly pathogenic avian influenza (HPAI) H5N1 virus and the recent global circulation of H1N1 swine-origin influenza virus in 2009 have highlighted the need for new anti-influenza therapies. This has been made all the more important with the emergence of antiviral-resistant strains. Recent progress in achieving three-dimensional (3D) crystal structures of influenza viral proteins and efficient tools available for pharmacophore-based virtual screening are aiding us in the discovery and design of new antiviral compounds. Areas covered: This review discusses pharmacophore modeling as a potential cost-effective and time-saving technology for new drug discovery as an alternative to high-throughput screening. Based on this technical platform, the authors discuss current progress and future prospects for developing novel influenza antivirals against pre-existing or emerging novel targets. Expert opinion: Although it might be at an infant stage of development, the availability of the 3D crystal structures of influenza viral proteins is expected to accelerate the application of structure-based drug design (SBDD) and pharmacophore modeling. Furthermore, the neuraminidase inhibitor, one of the most successful examples of a SBDD, still receives great attention because of its superb antiviral activities and the resistance of influenza strains to oseltamivir. However, despite much success, pharmacophore-based virtual screening exhibits limited predictive power in hit identification. Further improvements in pharmacophore detection algorithms, proper combinations of in silico methods as well as judicious choosing of compounds are expected to improve the hit rate. With the help of these technologies, the discovery of anti-influenza agents will be accelerated.

AB - Introduction: The emergence of the highly pathogenic avian influenza (HPAI) H5N1 virus and the recent global circulation of H1N1 swine-origin influenza virus in 2009 have highlighted the need for new anti-influenza therapies. This has been made all the more important with the emergence of antiviral-resistant strains. Recent progress in achieving three-dimensional (3D) crystal structures of influenza viral proteins and efficient tools available for pharmacophore-based virtual screening are aiding us in the discovery and design of new antiviral compounds. Areas covered: This review discusses pharmacophore modeling as a potential cost-effective and time-saving technology for new drug discovery as an alternative to high-throughput screening. Based on this technical platform, the authors discuss current progress and future prospects for developing novel influenza antivirals against pre-existing or emerging novel targets. Expert opinion: Although it might be at an infant stage of development, the availability of the 3D crystal structures of influenza viral proteins is expected to accelerate the application of structure-based drug design (SBDD) and pharmacophore modeling. Furthermore, the neuraminidase inhibitor, one of the most successful examples of a SBDD, still receives great attention because of its superb antiviral activities and the resistance of influenza strains to oseltamivir. However, despite much success, pharmacophore-based virtual screening exhibits limited predictive power in hit identification. Further improvements in pharmacophore detection algorithms, proper combinations of in silico methods as well as judicious choosing of compounds are expected to improve the hit rate. With the help of these technologies, the discovery of anti-influenza agents will be accelerated.

UR - http://www.scopus.com/inward/record.url?scp=84875383056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875383056&partnerID=8YFLogxK

U2 - 10.1517/17460441.2013.767795

DO - 10.1517/17460441.2013.767795

M3 - Review article

VL - 8

SP - 411

EP - 426

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 4

ER -